trending Market Intelligence /marketintelligence/en/news-insights/trending/_9pV34vlu5t1Ahp-j6-kag2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Bavarian Nordic to sell priority review voucher to unknown buyer for $95M

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Bavarian Nordic to sell priority review voucher to unknown buyer for $95M

Bavarian Nordic A/S has agreed to sell a priority review voucher that was obtained through the development of a smallpox and monkeypox vaccine for $95 million in cash.

The Danish biotechnology company did not disclose the buyer. The transaction is subject to customary closing conditions including antitrust review, which is expected to occur in early 2020.

The U.S. Food and Drug Administration granted Bavarian Nordic the priority review voucher in September upon the approval of the smallpox and monkeypox vaccine Jynneos.

Holders of priority review vouchers are granted accelerated review from the FDA for future human drug applications.

Jefferies International Ltd. served as the exclusive financial adviser to Bavarian Nordic for the sale.